Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Michael Friedrich, Simon Jasinski-Bergner, Maria Filothei Lazaridou, Karthikeyan Subbarayan, Chiara Massa, Sandy Tretbar, Anja Mueller, Diana Handke, Katharina Biehl, Jürgen Bukur, Marco Donia, Ofer Mandelboim, Barbara Seliger*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

Original languageAmerican English
Pages (from-to)1689-1700
Number of pages12
JournalCancer Immunology, Immunotherapy
Issue number10
StatePublished - 1 Oct 2019

Bibliographical note

Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.


  • Immune escape
  • Immunotherapy
  • MHC
  • Resistance
  • Tumor


Dive into the research topics of 'Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy'. Together they form a unique fingerprint.

Cite this